Semaglutide injections are now considered the secret miracle to losing weight, especially for those who have struggled with the scale for years
This chemical modification, developed by Theratechnologies, protects the peptide from degradation by dipeptidyl peptidase IV (DPP-IV), the main enzyme responsible for the short half-life of native GHRH
Retatrutide produced the largest weight loss of the class up to ~24.2% at 48 weeks in Phase 2 so the absolute amount of lean mass lost can be larger simply because total loss is larger
doi: 10.1002/ps.6713
It will offer a glimpse into the future as key trends play out that will shape how obesity is viewed, diagnosed and treated, while healthcare systems grapple with this formidable challenge
Patent protection for semaglutide, the active ingredient in Novo Nordisks blockbuster diabetes and weight loss drugs, has ended in several countries